Rallybio Q3 net loss widens to $18.4M; positive RLYB116 Phase 1 data with >99% C5 reduction

Rallybio Corp

2022-Q3 EPS reported -$1.65

Net loss $18.4M for Q3 2022, vs $10.2M for Q3 2021; net loss per share $0.60.
Cash, cash equivalents, and marketable securities $132.4M as of Sep 30, 2022; runway into Q1 2024.
RLYB212 Phase 1b shows rapid elimination of transfused platelets; proof-of-concept data expected Q1 2023.
RLYB116 Phase 1: >99% reduction in free C5 within 24 hrs at 100 mg SC; half-life >300 hrs; MAD study in Q1 2023.
R&D expenses $12.1M (up 142% YoY) driven by RLYB212 and RLYB116 development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Rallybio Corp reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 7, 2022, Rallybio Corporation issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Rallybio Corp filing history →

Source: SEC EDGAR

accession 0000950170-22-022335

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.